Unveiling the potential of HS-1793: a review of its anticancer properties and therapeutic promise.

IF 3.4 4区 医学 Q3 CHEMISTRY, MEDICINAL Future medicinal chemistry Pub Date : 2024-01-01 Epub Date: 2024-11-18 DOI:10.1080/17568919.2024.2424150
Xavier Capó, Manuel Jiménez-Garcia, Farukh Sharopov, Patrick Valere Tsouh Fokou, Miquel Martorell, Afaf Ahmed Aldahish, Raffaele Pezzani, Javad Sharifi-Rad, Daniela Calina
{"title":"Unveiling the potential of HS-1793: a review of its anticancer properties and therapeutic promise.","authors":"Xavier Capó, Manuel Jiménez-Garcia, Farukh Sharopov, Patrick Valere Tsouh Fokou, Miquel Martorell, Afaf Ahmed Aldahish, Raffaele Pezzani, Javad Sharifi-Rad, Daniela Calina","doi":"10.1080/17568919.2024.2424150","DOIUrl":null,"url":null,"abstract":"<p><p>HS-1793 is a novel derivative of resveratrol, a compound known for its numerous beneficial effects, including anticancer activity, anti-inflammatory response, antimicrobial, antiaging, anti-cardiovascular disease activity, neuroprotective activity, etc. Despite its wide and interesting properties, resveratrol suffers from a crucial flaw because it is low bioavailable. For this reason, many other derivatives were explored and among them, HS-1793 has caught the attention of researchers. HS-1793 is a synthetic derivative of resveratrol discovered in 2007 that has been shown to have anti-cancer and anti-inflammatory properties. In addition, the compound showed a positive profile in metabolic processes, with adequate pharmacokinetics and pharmacodynamics. This review highlights current research on HS-1793, evaluating <i>in vitro</i> and <i>in vivo</i> works and lays the foundation for novel explorative trials in human diseases.</p>","PeriodicalId":12475,"journal":{"name":"Future medicinal chemistry","volume":" ","pages":"2301-2311"},"PeriodicalIF":3.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11622770/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17568919.2024.2424150","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

HS-1793 is a novel derivative of resveratrol, a compound known for its numerous beneficial effects, including anticancer activity, anti-inflammatory response, antimicrobial, antiaging, anti-cardiovascular disease activity, neuroprotective activity, etc. Despite its wide and interesting properties, resveratrol suffers from a crucial flaw because it is low bioavailable. For this reason, many other derivatives were explored and among them, HS-1793 has caught the attention of researchers. HS-1793 is a synthetic derivative of resveratrol discovered in 2007 that has been shown to have anti-cancer and anti-inflammatory properties. In addition, the compound showed a positive profile in metabolic processes, with adequate pharmacokinetics and pharmacodynamics. This review highlights current research on HS-1793, evaluating in vitro and in vivo works and lays the foundation for novel explorative trials in human diseases.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
揭示 HS-1793 的潜力:综述其抗癌特性和治疗前景。
HS-1793 是白藜芦醇的一种新型衍生物,白藜芦醇因其多种有益作用而闻名,包括抗癌活性、抗炎反应、抗菌、抗衰老、抗心血管疾病活性、神经保护活性等。尽管白藜芦醇具有广泛而有趣的特性,但它有一个重要的缺陷,即生物利用率低。因此,研究人员对许多其他衍生物进行了探索,其中 HS-1793 引起了研究人员的注意。HS-1793 是 2007 年发现的一种白藜芦醇合成衍生物,已被证明具有抗癌和抗炎特性。此外,该化合物在新陈代谢过程中表现出良好的药代动力学和药效学特性。这篇综述重点介绍了 HS-1793 目前的研究情况,评估了体外和体内工作,为在人类疾病中进行新的探索性试验奠定了基础。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Future medicinal chemistry
Future medicinal chemistry CHEMISTRY, MEDICINAL-
CiteScore
5.80
自引率
2.40%
发文量
118
审稿时长
4-8 weeks
期刊介绍: Future Medicinal Chemistry offers a forum for the rapid publication of original research and critical reviews of the latest milestones in the field. Strong emphasis is placed on ensuring that the journal stimulates awareness of issues that are anticipated to play an increasingly central role in influencing the future direction of pharmaceutical chemistry. Where relevant, contributions are also actively encouraged on areas as diverse as biotechnology, enzymology, green chemistry, genomics, immunology, materials science, neglected diseases and orphan drugs, pharmacogenomics, proteomics and toxicology.
期刊最新文献
PROTACs in 2025: from the laboratory concept to clinical breakthrough. Discovery of novel 2,4-diarylaminopyrimidine derivatives as FAK inhibitors with potent anti-cancer potency. Key contemporary considerations for halogens in drug discovery. Targeting the cGAS-STING-TBK1 pathway in cancer therapy. Overcoming limitations of targeted protein degraders: developments toward reversible, self-assembling degraders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1